These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23000961)

  • 1. Effect of lipo-prostaglandin E1 on cystatin C, β2-microglobulin, and estimated glomerular filtration rate in patients with decompensated heart failure and renal dysfunction: a single-center, nonrandomized controlled study.
    Hou ZQ; Sun ZX; Su CY; Tan H; Zhong X; Hu B; Zhou Y; Shang DY
    Heart Vessels; 2013 Sep; 28(5):589-95. PubMed ID: 23000961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Alprostadil on the Prevention of Contrast-Induced Nephropathy: A Meta-Analysis of 36 Randomized Controlled Trials.
    Xie J; Jiang M; Lin Y; Deng H; Li L
    Angiology; 2019 Aug; 70(7):594-612. PubMed ID: 30669852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction.
    Hou ZQ; Sun ZX; Su CY; Tan H; Zhong X; Hu B; Zhou Y; Shang DY
    Cardiovasc Ther; 2013 Apr; 31(2):108-14. PubMed ID: 23490237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of prostaglandin E1, dobutamine and placebo on hemodynamic, renal and neurohumoral variables in patients with advanced heart failure.
    Wimmer A; Stanek B; Kubecova L; Vitovec J; Spinar J; Yilmaz N; Kos T; Hartter E; Frey B; Pacher R
    Jpn Heart J; 1999 May; 40(3):321-34. PubMed ID: 10506854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Change in Multiple Filtration Markers and Subsequent Risk of Cardiovascular Disease and Mortality.
    Rebholz CM; Grams ME; Matsushita K; Inker LA; Foster MC; Levey AS; Selvin E; Coresh J
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):941-8. PubMed ID: 25825481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial.
    Tang WHW; Dupont M; Hernandez AF; Voors AA; Hsu AP; Felker GM; Butler J; Metra M; Anker SD; Troughton RW; Gottlieb SS; McMurray JJ; Armstrong PW; Massie BM; Califf RM; O'Connor CM; Starling RC
    JACC Heart Fail; 2015 Jan; 3(1):40-49. PubMed ID: 25453534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preprocedure and Postprocedure Predictive Values of Serum β2-Microglobulin for Contrast-Induced Nephropathy in Patients Undergoing Coronary Computed Tomography Angiography: A Comparison With Creatinine-Based Parameters and Cystatin C.
    Li S; Zheng Z; Tang X; Peng L; Luo Y; Dong R; Zhao Y; Liu J
    J Comput Assist Tomogr; 2015; 39(6):969-74. PubMed ID: 26248154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased cystatin C levels as a risk factor of cardiovascular events in patients with preserved estimated glomerular filtration rate after elective percutaneous coronary intervention with drug-eluting stents.
    Sai E; Shimada K; Miyauchi K; Masaki Y; Kojima T; Miyazaki T; Kurata T; Ogita M; Tsuboi S; Yoshihara T; Miyazaki T; Ohsaka A; Daida H
    Heart Vessels; 2016 May; 31(5):694-701. PubMed ID: 25863806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure).
    Wan SH; Stevens SR; Borlaug BA; Anstrom KJ; Deswal A; Felker GM; Givertz MM; Bart BA; Tang WH; Redfield MM; Chen HH
    Circ Heart Fail; 2016 Aug; 9(8):. PubMed ID: 27512103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited value of cystatin-C over estimated glomerular filtration rate for heart failure risk stratification.
    Zamora E; Lupón J; de Antonio M; Vila J; Galán A; Gastelurrutia P; Urrutia A; Bayes-Genis A
    PLoS One; 2012; 7(12):e51234. PubMed ID: 23240006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events.
    Dupont M; Wu Y; Hazen SL; Tang WH
    Circ Heart Fail; 2012 Sep; 5(5):602-9. PubMed ID: 22899766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corticosteroids Significantly Increase Serum Cystatin C Concentration without Affecting Renal Function in Symptomatic Heart Failure.
    Zhai JL; Ge N; Zhen Y; Zhao Q; Liu C
    Clin Lab; 2016; 62(1-2):203-7. PubMed ID: 27012051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Changes in serum β2-microglobulin, retinol-binding protein, and cystatin C and their value in identifying early renal dysfunction in patients with chronic hepatitis B undergoing tenofovir or entecavir monotherapy: a comparative analysis].
    He J; Ning HB; Zeng YL; Li W; Li K; Shang J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Sep; 24(9):643-646. PubMed ID: 27788718
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of liposomal prostaglandin E1 on periprocedural myocardial injury in patients with unstable angina undergoing an elective percutaneous coronary intervention.
    Fan Y; Jiang Y; Fu X; Cai J; Wang Y; Li W; Gu X; Xing K; Bai S; Bi X
    Coron Artery Dis; 2015 Dec; 26(8):671-7. PubMed ID: 26267747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating levels of β2-microglobulin and cystatin C are associated with left atrial size: additional link between the kidney and the heart.
    Liu YS; Wang X; Jiang WD; Huang ZW; Wang YM; Hao L; Xing JL; Wang L; Liu XX; Lounsbury P; Zhang M; Lu QH
    Clin Nephrol; 2013 Sep; 80(3):168-76. PubMed ID: 23849305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-specific evolution of renal function in chronic heart failure patients dynamically predicts clinical outcome in the Bio-SHiFT study.
    Brankovic M; Akkerhuis KM; van Boven N; Anroedh S; Constantinescu A; Caliskan K; Manintveld O; Cornel JH; Baart S; Rizopoulos D; Hillege H; Boersma E; Umans V; Kardys I
    Kidney Int; 2018 Apr; 93(4):952-960. PubMed ID: 29191357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population.
    Astor BC; Shafi T; Hoogeveen RC; Matsushita K; Ballantyne CM; Inker LA; Coresh J
    Am J Kidney Dis; 2012 May; 59(5):653-62. PubMed ID: 22305758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury.
    Ahmad T; Jackson K; Rao VS; Tang WHW; Brisco-Bacik MA; Chen HH; Felker GM; Hernandez AF; O'Connor CM; Sabbisetti VS; Bonventre JV; Wilson FP; Coca SG; Testani JM
    Circulation; 2018 May; 137(19):2016-2028. PubMed ID: 29352071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF.
    Liu LC; Voors AA; Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Chen Y; Greenberg BH; Ponikowski P; Pang PS; Prescott MF; Hua TA; Severin TM; Metra M
    Clin Res Cardiol; 2016 Sep; 105(9):727-37. PubMed ID: 27017514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystatin C-based CKD-EPI equations and N-terminal pro-B-type natriuretic peptide for predicting outcomes in acutely decompensated heart failure.
    Flores-Blanco PJ; Manzano-Fernández S; Pérez-Calvo JI; Pastor-Pérez FJ; Ruiz-Ruiz FJ; Carrasco-Sánchez FJ; Morales-Rull JL; Pascual-Figal D; Galisteo-Almeda L; Januzzi JL
    Clin Cardiol; 2015 Feb; 38(2):106-13. PubMed ID: 25663560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.